Travel Medicine and Infectious Disease
Volume 7, Issue 1 , Pages 2-6 , January 2009

Mefloquine neurotoxicity: A literature review

  • Stephen Toovey

      Affiliations

    • Corresponding Author InformationPresent address: Burggartenstrasse 32, 4103 Bottmingen, Switzerland. Tel.: +41 61 421 7872; fax: +41 61 421 7063.

Received 4 December 2008 ,Accepted 10 December 2008.

References 

  1. van Nassauw L, Toovey S, Van Op den Bosch J, Timmermans JP, Vercruysse J. Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice. Travel Med Infect Dis. 2008;6(5):253–258
  2. Lydersen K. Family blames soldier's suicide on anti-malaria drug. Washington Post. 2008 Oct 12;A10:
  3. Bernard J, Le CJ, Sarrouy J, Renaudineau J, Geffray L, Dufour P, et al. [Toxic encephalopathy caused by mefloquine?]. Presse Med. 1987;16(33):1654–1655
  4. Ronn AM, Ronne-Rasmussen J, Gotzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health. 1998;3(2):83–88
  5. Caillon E, Schmitt L, Moron P. Acute depressive symptoms after mefloquine treatment. Am J Psychiatry. 1992;149(5):712
  6. Dankwa E, Martin P. Review on adverse events associated with lariam (mefloquine). Basel: Switzerland, Hoffmann-La Roche Ltd; 1997;Period: January 1 to December 31, 1996
  7. Harinasuta T, Bunnag D, Wernsdorfer WH. A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ. 1983;61(2):299–305
  8. Hennequin C, Bouree P, Bazin N, Bisaro F, Feline A. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Intern Med. 1994;154(20):2360–2362
  9. Kofi Ekue JM, Ulrich AM, Rwabwogo-Atenyi J, Sheth UK. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ. 1983;61(4):713–718
  10. Lebain P, Juliard C, Davy JP, Dollfus S. [Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases]. Encephale. 2000;26(4):67–70
  11. Luxemburger C, Nosten F, ter Kuiile F, Frejacques L, Chongsuphajaisiddhi T, White NJ. Mefloquine for multidrug-resistant malaria. Lancet. 1991;338(8777):1268
  12. Mai NTH, Chuong LV, Phu NH, Hien TT, Day NPJ, Waller D, et al. Post-malaria neurological syndrome. Lancet. 1996;348(9032):917–921
  13. Marsepoil T, Petithory J, Faucher JM, Ho P, Viriot E, Benaiche F. [Encephalopathy and memory disorders during treatments with mefloquine]. Rev Med Interne. 1993;14(8):788–791
  14. Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf. 2004;27(3):203–213
  15. Patchen LC, Campbell CC, Williams SB. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med. 1989;321(20):1415–1416
  16. Ronn AM, Bygbjerg IC. [Acute brain syndrome after mefloquine treatment]. Ugeskr Laeger. 1994;156(41):6044–6045
  17. Rouveix B, Bricaire F, Michon C, Franssen G, Lebras J, Bernard J, et al. Mefloquine and an acute brain syndrome. Ann Intern Med. 1989;110(7):577–578
  18. Sowunmi A, Salako LA, Oduola AM, Walker O, Akindele JA, Ogundahunsi OA. Neuropsychiatric side effects of mefloquine in Africans. Trans R Soc Trop Med Hyg. 1993;87(4):462–463
  19. Sowunmi A, Adio RA, Oduola AM, Ogundahunsi OA, Salako LA. Acute psychosis after mefloquine. Report of six cases. Trop Geogr Med. 1995;47(4):179–180
  20. Speich R, Haller A. Central anticholinergic syndrome with the antimalarial drug mefloquine. N Engl J Med. 1994;331(1):57–58
  21. Stuiver PC, Ligthelm RJ, Goud TJ. Acute psychosis after mefloquine. Lancet. 1989;2(8657):282
  22. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Ligthelm RJ, Overbosch D, Stricker BH. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther. 2002;72(3):294–301
  23. van Riemsdijk MM, Ditters JM, Sturkenboom MC, Tulen JH, Ligthelm RJ, Overbosch D, et al. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol. 2002;58(6):441–445
  24. Wittes RC, Saginur R. Adverse reaction to mefloquine associated with ethanol ingestion. CMAJ. 1995;152(4):515–517
  25. Ajana F, Fortier B, Martinot A, Rouveix B, Camus D. Mefloquine prophylaxis and neurotoxicity – report of a case. Sem Hop. 1990;66(17):918–919
  26. Dow G, Bauman R, Caridha D, Cabezas M, Du F, Gomez-Lobo R, et al. Mefloquine induces dose-related neurological effects in a rat model. Antimicrob Agents Chemother. 2006;50(3):1045–1053
  27. Nicolas X, Granier H, Laborde JP, Martin J, Talarmin F. Danger of self-administered malaria prophylaxy. Presse Med. 2001;30(27):1349–1350
  28. Borruat FX, Nater B, Robyn L, Genton B. Prolonged visual illusions induced by mefloquine (LariamR): a case report. J Travel Med. 2001;8(3):148–149
  29. Lobel HO, Baker MA, Gras FA, Stennies GM, Meerburg P, Hiemstra E, et al. Use of malaria prevention measures by North American and European travelers to East Africa. J Travel Med. 2001;8(4):167–172
  30. Petersen E, Ronne T, Ronn A, Bygbjerg I, Larsen SO. Reported side effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med. 2000;7(2):79–84
  31. Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health. 1996;1(4):485–494
  32. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, et al. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003;327(7423):1078
  33. Brumbaugh M, Price P, Fagan N, Hsieh H. Psychotic mania associated with mefloquine in a bipolar patient. South Med J. 2008;101(5):550–551
  34. Fujii T, Kaku K, Jelinek T, Kimura M. Malaria and mefloquine prophylaxis use among Japan Ground Self-Defense Force personnel deployed in East Timor. J Travel Med. 2007;14(4):226–232
  35. Jousset N, Guilleux M, de Gentile L, Le Bouil A, Turcant A, Rouge-Maillart C. [Spectacular suicide associated with mefloquine]. Presse Med. 2006;35(5 Pt 1):789–792
  36. Tran TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malar J. 2006;5:74
  37. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet. 1993;341(8856):1299–1303
  38. Potasman I, Beny A, Seligmann H. Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Travel Med. 2000;7(1):5–9
  39. Schlagenhauf P, Steffen R. Neuropsychiatric events and travel: do antimalarials play a role?. J Travel Med. 2000;7(5):225–226
  40. Overbosch D. Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. J Travel Med. 2003;10(Suppl 1):S16–S20
  41. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Tulen JH, Ligthelm RJ, Overbosch D, et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol. 2004;57(4):506–512
  42. Ollivier L, Tifratene K, Josse R, Keundjian A, Boutin JP. The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study. Ann Trop Med Parasitol. 2004;98(6):639–641
  43. Davis TM, Dembo LG, Kaye-Eddie SA, Hewitt BJ, Hislop RG, Batty KT. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol. 1996;42(4):415–421
  44. Vuurman EF, Muntjewerff ND, Uiterwijk MM, van Veggel LM, Crevoisier C, Haglund L, et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol. 1996;50(6):475–482
  45. Schlagenhauf P, Lobel H, Steffen R, Johnson R, Popp K, Tschopp A, et al. Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg. 1997;56(2):235–240
  46. Fusetti M, Eibenstein A, Corridore V, Hueck S, Chiti-Batelli S. [Mefloquine and ototoxicity: a report of 3 cases]. Clin Ter. 1999;150(5):379–382
  47. Wise M, Toovey S. Reversible hearing loss in temporal association with chemoprophylactic mefloquine use. Travel Med Infect Dis. 2007;5(6):385–388
  48. Hessen-Soderman AC, Bergenius J, Palme IB, Bergqvist Y, Hellgren U. Mefloquine prophylaxis and hearing, postural control, and vestibular functions. J Travel Med. 1995;2(2):66–69
  49. Berninger E, Karlsson KK, Alvan G. Quinine reduces the dynamic range of the human auditory system. Acta Otolaryngol. 1998;118(1):46–51
  50. Claessen FAP, van Boxtel CJ, Perenboom RM, Tange RA, Wetsteijn JCFM, Kager PA. Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Trop Med Int Health. 1998;3(6):482–489
  51. Jager W, Idrizbegovic E, Karlsson KK, Alvan G. Quinine-induced hearing loss in the guinea pig is not affected by the Ca2+ channel antagonist verapamil. Acta Otolaryngol. 1997;117(1):46–48
  52. Karlsson KK, Hellgren U, Alvan G, Rombo L. Audiometry as a possible indicator of quinine plasma concentration during treatment of malaria. Trans R Soc Trop Med Hyg. 1990;84(6):765–767
  53. Karlsson KK, Berninger E, Alvan G. The effect of quinine on psychoacoustic tuning curves, stapedius reflexes and evoked otoacoustic emissions in healthy volunteers. Scand Audiol. 1991;20(2):83–90
  54. Toovey S. Are currently deployed artemisinins neurotoxic?. Toxicol Lett. 2006;166(2):95–104
  55. Lo SH, Kotabe S, Mitsunaga L. Azithromycin-induced hearing loss. Am J Health Syst Pharm. 1999;56(4):380–383
  56. Mamikoglu B, Mamikoglu O. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol. 2001;110(1):102
  57. Ress BD, Gross EM. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol. 2000;109(4):435–437
  58. Taylor WR, Richie TL, Fryauff DJ, Ohrt C, Picarima H, Tang D, et al. Tolerability of azithromycin as malaria prophylaxis in adults in northeast Papua, Indonesia. Antimicrob Agents Chemother. 2003;47(7):2199–2203
  59. Hadi U, Nuwayhid N, Hasbini AS. Chloroquine ototoxicity: an idiosyncratic phenomenon. Otolaryngol Head Neck Surg. 1996;114(3):491–493
  60. Coutinho MB, Duarte I. Hydroxychloroquine ototoxicity in a child with idiopathic pulmonary haemosiderosis. Int J Pediatr Otorhinolaryngol. 2002;62(1):53–57
  61. Johansen PB, Gran JT. Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol. 1998;16(4):472–474
  62. Seckin U, Ozoran K, Ikinciogullari A, Borman P, Bostan EE. Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis. Rheumatol Int. 2000;19(5):203–204
  63. Barrenas ML. The influence of a melanin-binding drug on temporary threshold shift in humans. Scand Audiol. 1994;23(2):93–98
  64. Barrenas ML. Hair cell loss from acoustic trauma in chloroquine-treated red, black and albino guinea pigs. Audiology. 1997;36(4):187–201
  65. Barrenas ML, Holgers KM. Ototoxic interaction between noise and pheomelanin: distortion product otoacoustic emissions after acoustical trauma in chloroquine-treated red, black, and albino guinea pigs. Audiology. 2000;39(5):238–246
  66. Dow GS, Hudson TH, Vahey M, Koenig ML. The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro. Malar J. 2003;2:14
  67. Toovey S, Bustamante LY, Uhlemann AC, East JM, Krishna S. Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activity. Basic Clin Pharmacol Toxicol. 2008;103(3):209–213
  68. Shepard RD, Fletcher A. Use of (+)-mefloquine for the treatment of malaria with reduced side-effects. Int Patent Appl WO. 1998;9839003:
  69. Ngiam TL, Go ML. Stereospecific inhibition of cholinesterases by mefloquine enantiomers. Chem Pharm Bull (Tokyo). 1987;35(1):409–412
  70. Zhou C, Xiao C, McArdle JJ, Ye JH. Mefloquine enhances nigral gamma-aminobutyric acid release via inhibition of cholinesterase. J Pharmacol Exp Ther. 2006;317(3):1155–1160
  71. Margineanu DG, Klitgaard H. The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro. Brain Res Bull. 2006;71(1-3):23–28
  72. Cruikshank SJ, Hopperstad M, Younger M, Connors BW, Spray DC, Srinivas M. Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci U S A. 2004;101(33):12364–12369
  73. Gribble FM, Davis TM, Higham CE, Clark A, Ashcroft FM. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. Br J Pharmacol. 2000;131(4):756–760
  74. Pham YT, Nosten F, Farinotti R, White NJ, Gimenez F. Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther. 1999;37(1):58–61
  75. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of. Plasmodium falciparum. Nature. 2003;424(6951):957–961
  76. Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep–wake regulation. Prog Neurobiol. 2004;73(6):379–396
  77. Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomelli D, Shiromani PJ. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep. 2003;26(8):943–947
  78. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem. 2001;8(4):371–384
  79. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett. 2002;127(1-3):269–277
  80. Barraud de Lagerie S, Comets E, Gautrand C, Fernandez C, Auchere D, Singlas E, et al. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol. 2004;141(7):1214–1222
  81. Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther. 2006;80(4):367–374
  82. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 2004;98(5):261–267

PII: S1477-8939(08)00154-3

doi: 10.1016/j.tmaid.2008.12.004

Travel Medicine and Infectious Disease
Volume 7, Issue 1 , Pages 2-6 , January 2009

Article Tools